Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Transitioning to high margin software revenue

Austco Healthcare
3:27pm
January 15, 2024
Austco Healthcare (AHC) develops a range of hardware and software products focused on enhancing communication between patients and primary carers within the hospital. Its key products are master call points (nurse call) and real-time location systems (RTLS) along with a growing high margin recurring model for its software packages. AHC generates 80% of revenue through hardware sales and 20% through software sales. Management is transitioning the business to a 50/50 split between hardware and software revenue which should result in higher margins. AHC expects strong organic growth to continue, while augmenting its offering and accelerating its growth strategy through acquiring technologies complementary to its current offering.

December trading activity

Aust Securities Exchange
3:27pm
January 9, 2024
ASX has recently released its monthly trading activity report for December 2023. It was a better trading month overall for ASX, in our view, with higher cash markets activity (+13%), an uptick in capital raisings (vs the softer pcp) and stronger Futures volumes. However, for the half, it was more of a mixed outcome. Our FY24-FY26 EPS forecasts are lowered by ~1% factoring in the recent trading activity. Our price target is lowered to A$60.20 (from A$60.70) largely on changes to our 1H24 assumptions post the recent release. Hold maintained.

Progress to towards clinical trial start

Tissue Repair
3:27pm
January 8, 2024
Tissue Repair (TRP) expects the Phase 3 trial for venous leg ulcers (VLU) to start recruiting in 4Q24 and top-line results to be reported late CY25. The National Institute of Health estimates the cost of treating VLUs at between US$2.5bn and US$3.5bn in the US. Following a review of our research universe, we revise our coverage approach for TRP. While we will continue to monitor and provide updates, we will cease providing a rating, valuation and forecasts. Thus, our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

Capital raise provides some runway

Control Bionics
3:27pm
January 3, 2024
CBL has completed a capital raising that will provide funds for new product commercialisation and approvals together with working capital to drive sales of the current products. Cashflow has been an ongoing issue with CBL and the capital raising provides some runway to deliver on the strategy set by new CEO Jeremy Steele, although it will be tight. After diluting for the capital raising our valuation has reduced to A$0.058 (from A$0.09). We maintain our Hold recommendation and will closely monitor the quarterly cashflow reports for signs of sales growth and cost control.

Strong finish to CY23

GQG Partners
3:27pm
January 2, 2024
We expect GQG to close FY23 (Dec-23) with ~US$118bn in FUM, +13.4% in 2H23. Flows momentum has been solid in recent months, which we expect continued in Dec-23. We estimate ~US$1.2bn net inflows for Dec-23 (US$10.2bn for CY23). GQG commences FY24 with group FUM ~8.7% above average 2H23 levels and ~16% above average FY23 FUM. We mark-to-market earnings on recent FUM moves leading to EPS upgrades. We continue to view GQG’s valuation as attractive (~10.7x FY24 PE); with executing on the broader diversification strategy likely required for a further and sustained valuation re-rating. Add maintained.

Mojo slows

Motorcycle Holdings
3:27pm
December 21, 2023
MTO have guided to 1H24 underlying EBITDA (pre-AAS16) of A$14-16m, down ~17% on the pcp (A$18.1m); and 36% below 2H23 (A$23.3m). The lower-than-expected guidance has been attributed to slowing sales demand within its wholesale new vehicle segment (Mojo) and increasing competitive pressures impacting margins. While we remain positive on the MTO business and broader strategy, Mojo’s diversified earnings base in mitigating a softer consumer backdrop had been a key element to our investment case. Given the guidance commentary and sharp deterioration in recent trade, the near-term outlook for the division is less certain. We lower our recommendation to a Hold, as we look for improved confidence and greater stability in the near-term earnings outlook of the combined business.

Funding the pipeline

Syntara
3:27pm
December 20, 2023
SNT is undertaking a A$10m equity raising via a two-tranche placement as well seeking to raise an additional A$2.2m via an SPP. The funds will be used towards the completion of three Phase 2 clinical trials in myelofibrosis, scarring and Parkinson’s disease. Following a review of our research universe, we revise our coverage approach for Syntara (SNT.AU). While we will continue to monitor and provide updates, we will cease providing a rating, valuation and forecasts. Thus, our forecasts, target price and recommendation should no longer be relied upon for investment decisions.

A tough environment blunting overall progress

PEXA Group
3:27pm
December 20, 2023
PXA has finalised its acquisition of Smoove and given a financial update. The trading update was soft overall with numerous headwinds across PXA’s operations. The financials for Smoove had been disclosed previously, and while this business provides a new avenue for growth, it is currently loss making. We lower our PXA FY25F/FY26F EPS by ~13%-17% factoring in revised FY24 guidance commentary and the inclusion of Smoove into our numbers. We lower our PXA price target to A$11.65 (from A$13.36) and move to a HOLD rating.

Now is the time to be BOLD

Avita Medical
3:27pm
December 19, 2023
We expect AVH will have significant share price moving newsflow when they update the market in February. In particular we are focused on updated quarterly revenue guidance, full year revenue guidance (we forecast growth of ~40%), a regulatory update on RECELL GO and most importantly a pointer to which quarter in CY25 the company plans to achieve positive cash flow. AVH is one of our key healthcare picks in 2024. We have made no changes to forecasts, valuation or target price and transfer coverage to Emily Porter. We maintain our Add recommendation.

Growing presence in WA

Monash IVF
3:27pm
December 19, 2023
MVF has announced it is growing its presence in Western Australia through the acquisition of Fertility North for an up-front cash payment of $12.0m. Recent industry cycle volumes as reported by Medicare show industry cycles for November were up 16% on the previous month and up ~4% on a four-month average on last year. We expect MVF will continue to gain market share benefitting from contributions of its acquisitions (PIVET medical and ART Associates). We have upgraded our FY24 forecasts to incorporate recent 1H24 guidance and have upgraded FY25/26 to include the benefit of the acquisition. Our target price has increased to $1.50 (from $1.29) and we maintain our Add recommendation.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more